NEW YORK (GenomeWeb News) – Shares of Compugen jumped 35 percent in early Monday trade on the Nasdaq after the firm announced that it had a new drug target for multiple epithelial tumors using its Monoclonal Antibody Targets Discovery Platform.

The firm's stock rose $1.42 to $5.50 within the first 20 minutes of the market's open. It was the second such spike in Compugen's stock within the past week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."